We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak

By LabMedica International staff writers
Posted on 29 May 2026

QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak. More...

The assays are designed for integration with the QIAcuity digital PCR system and for use by qualified laboratories in research, wastewater surveillance, and other environmental monitoring workflows. They were developed using publicly available genomic sequence information released during the outbreak response.

The new assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by the company. On the QIAcuity platform, dPCR enables sensitive nucleic acid detection and quantification across research applications, including infectious disease research and environmental surveillance, and the assays are part of a broader Sample to Insight portfolio that spans sample preparation through sequencing and analysis.

The assays are intended strictly for research use and are not intended for diagnostic procedures. They are available through a custom assay workflow on a make-to-order basis targeting the NP and VP35 regions. Complementary products available from stock include QIAseq sequencing panels and sample preparation and molecular workflow kits to support nucleic acid processing for downstream dPCR and next-generation sequencing (NGS).

The availability of these tools highlights the role of adaptable molecular technologies in supporting public health research infrastructure as genomic information emerges during outbreak responses. Combined with the QIAcuity system, the portfolio enables laboratories to rapidly adapt existing workflows as new pathogen targets arise. 

“Public health preparedness depends on the ability of laboratories to evaluate emerging pathogen targets as reliable genomic information becomes available,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “QIAGEN is committed to supporting customers around the world with adaptable molecular technologies that help strengthen infectious disease research and surveillance capacity. Our goal remains clear: no country should be left behind when new threats emerge.” 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.